iCAD (NASDAQ: ICAD) announced first-year data from the company's ExBRT ("A Safety and Efficacy Study of Intra-Operative Radiation Therapy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE